Certain underlying diseases such as diabetic mellitus and hypertension are a risk factor for the severity and mortality of coronavirus disease (COVID-19) patients. Furthermore, both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are controversial at role in the process of COVID-19 cases. The aim of the study was to investigate whether underlying diseases and taking ACEi/ARBs, affect the duration of hospitalization and mortality in patients with confirmed COVID-19. Medical usage claims data for the past three years until 15 May 2020, from the “CORONA-19 International Cooperation Research” project was used. We analyzed the medical insurance claims data for all 7590 coronavirus (COVID-19) patients confirmed by RT-PCR tests nationwide up to 15 May 2020. Among the comorbidities, a history of hypertension (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.056–2.158) and diabetes (HR, 1.867; 95% CI, 1.408–2.475) were associated significantly with mortality. Furthermore, heart failure (HR, 1.391; 95% CI, 1.027–1.884), chronic obstructive pulmonary disease (HR, 1.615; 95% CI, 1.185–2.202), chronic kidney disease (HR, 1.451; 95% CI, 1.018–2.069), mental disorder (HR, 1.61; 95% CI, 1.106–2.343), end stage renal disease (HR, 5.353; 95% CI, 2.185–13.12) were also associated significantly with mortality. The underlying disease has increased the risk of mortality in patients with COVID-19. Diabetes, hypertension, cancer, chronic kidney disease, heart failure, and mental disorders increased mortality. Controversial whether taking ACEi/ARBs would benefit COVID-19 patients, in our study, patients taking ACEi/ARBs had a higher risk of mortality.
【저자키워드】 COVID-19, underlying disease, medical treatment, 【초록키워드】 coronavirus disease, coronavirus, Mortality, severity, Cancer, Comorbidities, Chronic kidney disease, diabetes, underlying disease, risk factor, hypertension, angiotensin converting enzyme, Mental Disorders, Mental disorder, heart failure, Patient, Kidney disease, receptor, cooperation, inhibitor, underlying diseases, renal disease, disease, patients, COVID-19 patients, pulmonary disease, ACEi, Angiotensin II, RT-PCR test, angiotensin, chronic obstructive pulmonary disease, ARBs, COVID-19 cases, obstructive pulmonary disease, Receptor Blockers, international cooperation, PCR tests, Diabetic, RT-PCR tests, higher risk, 95% CI, 95% confidence interval, enzyme, hazard ratio, increased mortality, disorder, blocker, renal, ACEi/ARB, Affect, Mental, duration of hospitalization, benefit, analyzed, was used, significantly, diabete, chronic obstructive, increased the risk, patients with COVID-19, 【제목키워드】 drug, Presence,